Asset profile
Stempeucel · Stempeucel
Cell therapy
Evidence outlook · lead readout
NCT00883870 · Critical Limb Ischemia
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT00883870: The study was randomized and triple-blind with a placebo control, but it enrolled only 20 participants and its primary clinical endpoint was adverse events and symptomatic relief at 6 months. Because no results are posted, it is not possible to determine whether the primary endpoint was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.